For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and Tafamidis meglumine represents a genuine change. These groundbreaking therapies preserve the transthyretin protein, halting its destructive build-up and lessening the seve